Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Market Capitalization on January 27, 2025: USD 1.27 B

Changchun BCHT Biotechnology Co. Market Capitalization is USD 1.27 B on January 27, 2025, a -56.91% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Changchun BCHT Biotechnology Co. 52-week high Market Capitalization is USD 3.17 B on February 29, 2024, which is 150.09% above the current Market Capitalization.
Changchun BCHT Biotechnology Co. 52-week low Market Capitalization is USD 1.24 B on September 18, 2024, which is -1.82% below the current Market Capitalization.
Changchun BCHT Biotechnology Co. average Market Capitalization for the last 52 weeks is USD 1.89 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years